4599543
Last Update Posted: 2020-10-27
Recruiting has not begun
All Genders accepted | Under |
36 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia
A Study of IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia.
This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory CD123+ acute myeloid leukemia. The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 36 patients will be enrolled. Primary objective is to explore the safety, main consideration is dose-related safety.
Eligibility
Relevant conditions:
Acute Myeloid Leukemia
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
He Huang, PhD
hehuangyu@126.com
86-13605714822
Yongxian Hu, PhD
huyongxian2000@aliyun.com
86-15957162012
Data sourced from ClinicalTrials.gov